Lorlatinib granted breakthrough therapy status

On April 27, 2017, the FDA granted Pfizer Breakthrough Status on lorlatinib for patients previously treated with one or more ALK inhibitors. So you don’t have to take Crizotinib first, any of the other 3 will do. Also a Phase 3 CROWN study (NCT03052608) has begun enrolling patients.

This entry was posted in Brain metastases, lorlatinib - Lorbrena by Pfizer, Lung cancer, Potential Treatments, Research. Bookmark the permalink.

Leave a Reply